InsidersTradesSigma
ORASURE TECHNOLOGIES INC Stock: price and management transactions · United States · SEC (Form 4)
Follow the ORASURE TECHNOLOGIES INC stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, ORASURE TECHNOLOGIES INC has logged 62 insider filings. Market capitalisation: €300.9m. The latest transaction was disclosed on 30 June 2026 (Attribution). Among the most active insiders: Datin James A. The full history is free.
62
Insider Decl.
0
Thresholds
€63,483
1 ops.
Buy Volume
·
0 ops.
Sell Volume
46Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 23,879 of 25,484 companies
17.7
score / 100
Value10
Quality25
FCF yld-18%
Earn yld-23%
EV/EBITDA·
ROE-21%
Gross mgn42%
Net mgn-60%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 30 June 2026
Declarations62 total
3,666 sharesCommon StockSEC:0001470831-26-000683:0
46,106 shares0Common StockSEC:0001470831-26-000516:0
46,106 shares0Common StockSEC:0001470831-26-000515:0
22,888 shares@ US$3.020.029% mcap100.0% of flowCommon StockSEC:0001470831-26-000437:0
28,406 shares@ US$3.020.035% mcap26.3% of flowCommon StockSEC:0001470831-26-000438:0
25,000 shares@ US$2.980.031% mcap100.0% of flowCommon StockSEC:0001470831-26-000443:0
Ideal exit: 6 Feb 2027 (T+270)
21,305 shares@ US$3.020.027% mcap34.9% of flowCommon StockSEC:0001470831-26-000436:0
33,661 shares0Common StockSEC:0001470831-26-000442:0
5,623 shares@ US$2.89010.0074% mcap6.5% of flowCommon StockSEC:0001062993-22-015567:0
1,963 shares@ US$6.21250.0056% mcap7.4% of flowCommon StockSEC:0001062993-22-015121:0
814,830 shares@ US$4.9091.80% mcap100.0% of flowCommon StockSEC:0001062993-22-014386:0
24,983 shares@ US$4.00270.045% mcap68.6% of flowCommon StockSEC:0001062993-22-014388:0
2,104 shares@ US$4.1250.0039% mcap2.9% of flowCommon StockSEC:0001062993-22-014074:0
1,996 shares@ US$5.530.0051% mcap1.7% of flowCommon StockSEC:0001062993-22-013327:0
3,399 shares@ US$5.250.0083% mcap34.9% of flowCommon StockSEC:0001062993-22-012896:0
2,957 shares@ US$5.250.0072% mcap11.0% of flowCommon StockSEC:0001062993-22-012894:0
20,000 shares@ US$5.250.049% mcap42.6% of flowCommon StockSEC:0001062993-22-012899:0
20,000 shares@ US$5.250.049% mcap52.6% of flowCommon StockSEC:0001062993-22-012923:0
4,928 shares@ US$5.250.012% mcap8.9% of flowCommon StockSEC:0001062993-22-012901:0
2,745 shares@ US$5.250.0067% mcap25.9% of flowCommon StockSEC:0001062993-22-012898:0
20,000 shares@ US$5.250.049% mcap36.9% of flowCommon StockSEC:0001062993-22-012897:0
2,409 shares@ US$5.250.0059% mcap34.9% of flowCommon StockSEC:0001062993-22-012900:0
1,606 shares@ US$5.0550.0037% mcap1.6% of flowCommon StockSEC:0001062993-22-012238:0
2,247 shares@ US$6.710.0067% mcap25.9% of flowCommon StockSEC:0001062993-22-009987:0
14,815 shares0Common StockSEC:0001593968-22-000835:0
25 of 62 declarations
About ORASURE TECHNOLOGIES INC
OraSure Technologies Inc. (ticker: OSUR) is a U.S.-based healthcare diagnostics company listed on the NASDAQ in the United States. For French-speaking investors, the equity story sits at the intersection of point-of-care diagnostics, home testing, and sample collection/stabilization technologies. The company was founded in 1987 as SolarCare in Bethlehem, Pennsylvania, and later became OraSure Technologies in 2000 when it entered the public market. Its long operating history and regulatory know-how are part of its core investment appeal. ([orasure.com](https://orasure.com/company.html)) OraSure’s business is broadly organized around two pillars. First, it develops and commercializes rapid diagnostic tests, with the OraQuick platform being the most recognizable franchise. These products have historically covered infectious-disease screening such as HIV, hepatitis C, and syphilis, alongside other critical conditions and public-health applications. Second, the company sells sample collection and stabilization solutions used in molecular diagnostics, genomics research, microbiome studies, and pharmaceutical workflows. Its portfolio is designed to support multiple specimen types, including saliva, oral fluid, urine, skin cells, blood, and stool. That combination gives OraSure a differentiated position versus pure-play diagnostics peers. ([orasure.com](https://orasure.com/company.html)) From a competitive standpoint, OraSure is a niche player rather than a broad diversified medtech platform. Its strengths include a deep legacy in self-testing and point-of-need diagnostics, a recognized brand in certain infectious-disease categories, and a complementary sample-management franchise. At the same time, the company remains exposed to demand variability in public-health funding, changes in testing algorithms or reimbursement conditions, product adoption cycles, and competition from newer or lower-cost technologies. Management has emphasized regulatory execution, product innovation, and commercial channel expansion as key levers for future growth. ([orasure.gcs-web.com](https://orasure.gcs-web.com/news-releases/news-release-details/orasure-announces-fourth-quarter-2025-financial-results?utm_source=openai)) Recent developments matter for equity investors. In February 2026, OraSure said it expected to return to growth in 2026, supported by planned launches of a rapid molecular self-test for Chlamydia and Gonorrhoeae and its Colli-Pee™ at-home urine collection device for STI applications. In March 2025, the board authorized a $40 million share repurchase program over 24 months, funded from cash on hand, which signals confidence in the balance sheet and capital allocation discipline. The company also referenced a 2025 operational reset and ongoing efforts to stabilize demand and diversify its customer base. In short, OSUR is a NASDAQ-listed U.S. healthcare name with a focused diagnostics franchise, recurring regulatory catalysts, and meaningful execution risk. ([orasure.gcs-web.com](https://orasure.gcs-web.com/news-releases/news-release-details/orasure-announces-fourth-quarter-2025-financial-results?utm_source=openai))
